Recent Updates
Recently added Catalysts

Intermittent dosing of AZD5363

Phase 1

Metastatic Castrate-Resistant Prostate Cancer (mCRPC), | Small molecule | Oncology |AstraZeneca PLC|Last Updated: Jun 19, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment59

FDA Designations

No designations recorded

Clinical trial landscape

Intermittent dosing of AZD5363 · 1 trial · 6 indications

Phase 1 1
NCT01692262Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.Metastatic Castrate-Resistant Prostate Cancer (mCRPC),
COMPLETED59 Analytics
PHASE1COMPLETED
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),
NCT0169226259
Unlock trial analytics

Study Endpoints

Primary Endpoints

Parts A and B: Anti-tumour activity by measurement of changes in circulating prostate-specific antigen (PSA)
PSA measured from baseline for every 4 weeks. Primary assessment is at 12 weeks
Parts A and B: Anti-tumour activity by measurement of changes in circulating tumour cells (CTC)
CTC measured from baseline for every 4 weeks to week 12 (primary assessment) then measured every 12 weeks
Parts A and B: Anti-tumour activity by measurement of malignant soft tissue response rate
Tumour assessments by RECIST v1.1 every 12 weeks from baseline up to disease progression or withdrawal of consent
Parts A and B: Anti-tumour activity by measurement of metastatic bone disease status
Bone lesion assessments by bone scan (PCWG2) criteria every 12 weeks from baseline up to disease progression or withdrawal of consent.

Secondary Endpoints

Parts A and B: Safety and tolerability of AZD5363 in terms of adverse events, serious adverse events (including death) and safety measures: ECG, ECHO/MUGA, physical examination, pulse, blood pressure, weight and laboratory variables
Routine safety assessments, throughout the period that patients receive AZD5363 up to 28 days following discontinuation of study treatment.
Parts A and B: AZD5363 PK: time to maximum plasma concentration, terminal rate constant,terminal half life, area under plasma concentration time curve, plasma clearance & volume of distribution
Multiple AZD5363 PK blood sample assessments.AZD5363 plasma concentration blood samples will be taken on Day 1(pre-dose,2,4,8 hours post-dose);D2(pre-dose);D8(continous) or D11(intermittent) (pre-dose and at 2,4,and 8 hours post-dose);D15,Cyc
Parts A and B: Plasma concentrations of pharmacodynamic (PD) biomarker
Multiple PD blood sample assessments.PD blood samples will be taken on the same schedule as PK sample and then Day 1 of every 12 weeks thereafter, and at the discontinuation visit
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeSCREENING

Treatment Arms

ArmTypeDescription
Part A Group 1 IntermittentEXPERIMENTALRecruitment suspended and will not be re-opened. See intervention description below.
Part A Group 2 IntermittentEXPERIMENTALRecruitment complete. See intervention description below.
Part BEXPERIMENTALThis part of the study will not be conducted following a review of data from Part A. See intervention description below.

Interventions

NameTypeDescription
Intermittent dosing of AZD5363DRUGIntermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexMALE
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: * Provision of informed consent * Males aged 18 years and older * Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features for which no standard therapy is currently considered appropriate * Documented evidence of Meta...

Countries:United StatesUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about Intermittent dosing of AZD5363

What is AZD5363 used for in metastatic castrate-resistant prostate cancer?

AZD5363 is an investigational small molecule being studied for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). It is being evaluated for its safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and tumour response in this patient population. The drug is not approved and remains in clinical development.

Who is developing AZD5363?

AZD5363 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical research to evaluate the drug's potential in oncology, specifically for metastatic castrate-resistant prostate cancer.

What phase is AZD5363 in?

AZD5363 is in Phase 1 clinical development. A Phase 1 trial has been completed to investigate the drug's safety, tolerability, and efficacy in patients with metastatic castrate-resistant prostate cancer. The drug is investigational and has not received regulatory approval.

What clinical trials is AZD5363 in?

AZD5363 has one completed clinical trial registered as NCT01692262, titled 'Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.' This Phase 1 study enrolled 59 male participants aged 18 years and older and was conducted in the United States and the United Kingdom.

Is AZD5363 the same as any other drug?

AZD5363 is the drug name used in clinical research for this investigational small molecule. No alternative names have been established in the available clinical trial information. The drug is being studied under this identifier in the context of prostate cancer research.